Japan s cabinet approved 3.7 bln U.S. dollars in emergency spending in reserve funds to combat the ongoing COVID-19 pandemic on Friday.
Using an allocation of 311.93 billion yen (2.99 billion U.S. dollars), the Japanese government will, controversially, extend the Go To Travel campaign which was set to end in January for another five months to purportedly bolster the nation s ailing tourism sector and help boost the broader economy.
The government will also use 73.69 billion yen (708.11 million U.S. dollars) to provide low-income single parents with more financial support. A total of 11.5 trillion yen (110.49 billion U.S. dollars) has been set aside under its two extra budgets for fiscal 2020 through next March to focus directly on the downside economic effects caused by the pandemic.
AstraZeneca pulls out of bid to hold Covid-19 vaccine trials in Philippines; virus cases almost reaching 450,000
thestar.com.my - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestar.com.my Daily Mail and Mail on Sunday newspapers.
Japan s cabinet approves US$3 7bil in emergency spending on Covid-19
thestar.com.my - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestar.com.my Daily Mail and Mail on Sunday newspapers.
Adjust font size:
MANILA, Dec. 11 (Xinhua) AstraZeneca, the Britain-based drug maker, has withdrawn its application to conduct COVID-19 vaccine clinical trials in the Philippines, the country s Food and Drug Administration (FDA) said on Friday. They (AstraZeneca) said they have enough data already, Enrique Domingo, the FDA director general, said in a text message to Xinhua, explaining the reason AstraZeneca cited for withdrawing trials application.
AstraZeneca last month applied to conduct the coronavirus vaccine clinical trials in the philippines, and it had already passed the ethics board when it decided to withdraw.
AstraZeneca can still supply the country with coronavirus vaccines without holding trials in the Philippines, Domingo said.
2020-12-11 12:36:10 GMT2020-12-11 20:36:10(Beijing Time) Xinhua English
MANILA, Dec. 11 (Xinhua) AstraZeneca, the Britain-based drug maker, has withdrawn its application to conduct COVID-19 vaccine clinical trials in the Philippines, the country s Food and Drug Administration (FDA) said on Friday. They (AstraZeneca) said they have enough data already, Enrique Domingo, the FDA director general, said in a text message to Xinhua, explaining the reason AstraZeneca cited for withdrawing trials application.
AstraZeneca last month applied to conduct the coronavirus vaccine clinical trials in the philippines, and it had already passed the ethics board when it decided to withdraw.
AstraZeneca can still supply the country with coronavirus vaccines without holding trials in the Philippines, Domingo said.